BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 19851209)

  • 21. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
    Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
    Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
    Shield PW; Papadimos DJ; Walsh MD
    Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneous carcinomas of the breast and ovary: utility of Pax-8, WT-1, and GATA3 for distinguishing independent primary tumors from metastases.
    Espinosa I; Gallardo A; D'Angelo E; Mozos A; Lerma E; Prat J
    Int J Gynecol Pathol; 2015 May; 34(3):257-65. PubMed ID: 25844549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas.
    Santin AD; Diamandis EP; Bellone S; Marizzoni M; Bandiera E; Palmieri M; Papasakelariou C; Katsaros D; Burnett A; Pecorelli S
    Am J Obstet Gynecol; 2006 May; 194(5):1296-302. PubMed ID: 16647913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.
    Santin AD; Diamandis EP; Bellone S; Soosaipillai A; Cane S; Palmieri M; Burnett A; Roman JJ; Pecorelli S
    Clin Cancer Res; 2005 May; 11(9):3320-5. PubMed ID: 15867230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Expression of fascin and CK14 in different histological types of cancer and its differential diagnostic significance].
    Xue LY; Zou SM; Zheng S; Xie YQ; Wen P; Liu XY; Lin DM; Lü N
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):838-44. PubMed ID: 21223690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas.
    Ciampa A; Fanger G; Khan A; Rock KL; Xu B
    Cancer; 2004 Dec; 102(6):368-72. PubMed ID: 15558786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
    Maxwell GL; Chandramouli GV; Dainty L; Litzi TJ; Berchuck A; Barrett JC; Risinger JI
    Clin Cancer Res; 2005 Jun; 11(11):4056-66. PubMed ID: 15930340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
    Brustmann H
    Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TTF-1 expression in ovarian and uterine epithelial neoplasia and its potential significance, an immunohistochemical assessment with multiple monoclonal antibodies and different secondary detection systems.
    Zhang PJ; Gao HG; Pasha TL; Litzky L; Livolsi VA
    Int J Gynecol Pathol; 2009 Jan; 28(1):10-8. PubMed ID: 19047914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Papillary serous carcinoma of peritoneum: case study and review of the literature on the differential diagnosis of malignant peritoneal tumors.
    Koutselini HA; Lazaris AC; Thomopoulou G; Papayannopoulou A; Kairi-Vasilatou E
    Adv Clin Path; 2001 Jul; 5(3):99-104. PubMed ID: 11753882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
    Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG
    Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.
    Hogg R; Scurry J; Kim SN; Friedlander M; Hacker N
    Gynecol Oncol; 2007 Jul; 106(1):44-51. PubMed ID: 17467045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts.
    Nezhat F; Cohen C; Rahaman J; Gretz H; Cole P; Kalir T
    Cancer; 2002 Jun; 94(11):2935-40. PubMed ID: 12115382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential expression of WT-1 in serous carcinomas in the peritoneum with or without associated serous carcinoma in endometrial polyps.
    Euscher ED; Malpica A; Deavers MT; Silva EG
    Am J Surg Pathol; 2005 Aug; 29(8):1074-8. PubMed ID: 16006803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
    Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
    Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hobnail-like cells in serous borderline tumor do not represent concomitant incipient clear cell neoplasms.
    Ohishi Y; Oda Y; Kurihara S; Kaku T; Yasunaga M; Nishimura I; Okuma E; Kobayashi H; Wake N; Tsuneyoshi M
    Hum Pathol; 2009 Aug; 40(8):1168-75. PubMed ID: 19368953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
    O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
    Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paratesticular müllerian-type papillary serous tumor in a child.
    Cohen MC; Shawis R; Evans C
    Pediatr Dev Pathol; 2009; 12(4):297-300. PubMed ID: 19348511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage.
    Brustmann H; Naudé S
    Gynecol Oncol; 2002 Jan; 84(1):47-52. PubMed ID: 11748975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.